Dexelvucitabine - Revision history

Prab: CSV import

2025-02-24T23:54:26Z

CSV import

← Older revision		Revision as of 23:54, 24 February 2025
Line 29:		Line 29:
	[[Category:Antiretroviral drugs]]		[[Category:Antiretroviral drugs]]
	[[Category:Nucleoside analog reverse transcriptase inhibitors]]		[[Category:Nucleoside analog reverse transcriptase inhibitors]]
			== Dexelvucitabine ==
			<gallery>
			File:Dexelvucitabine.svg\|Dexelvucitabine
			</gallery>

Prab: CSV import

2025-02-15T10:59:51Z

CSV import

← Older revision		Revision as of 10:59, 15 February 2025
Line 1:		Line 1:
	'''Dexelvucitabine''' is a nucleoside ~~analogue antiretroviral medication~~ that was ~~under investigation~~ for the treatment of [[HIV/AIDS]]. It is a synthetic ~~analogue~~ of ~~deoxycytidine, designed~~ to ~~interfere with~~ the ~~life cycle~~ of the [[~~HIV~~]] ~~virus, thereby reducing~~ the viral ~~load in infected individuals. Despite initial research, development of dexelvucitabine was halted due to concerns over its safety profile and efficacy in comparison to other available treatments~~.		{{Short description\|An antiretroviral drug}}
			{{Drugbox
			\| verifiedfields = changed
			\| verifiedrevid = 477002123
			\| image = Dexelvucitabine.svg
			\| image_size = 200px
			\| image_alt = Structural formula of Dexelvucitabine
			}}

			'''Dexelvucitabine''' is a [[nucleoside reverse transcriptase inhibitor]] (NRTI) that was investigated for the treatment of [[HIV/AIDS]]. It is a synthetic analog of [[cytosine]] and was developed to inhibit the replication of the [[human immunodeficiency virus]] (HIV) by interfering with the viral [[reverse transcriptase]] enzyme.

	==Mechanism of Action==		==Mechanism of Action==
	Dexelvucitabine ~~exerts its antiviral effects~~ by ~~acting as a competitive inhibitor of [[HIV~~ reverse transcriptase~~]], an~~ enzyme ~~critical for the~~ viral ~~replication process~~. ~~By incorporating itself~~ into the ~~viral~~ DNA, dexelvucitabine ~~causes~~ chain ~~termination~~. This ~~prevents the completion~~ of ~~the~~ DNA synthesis ~~necessary for the replication of~~ the ~~HIV virus, leading to a decrease in~~ viral load in ~~the patient~~.		Dexelvucitabine works by mimicking the natural nucleosides that are used by the reverse transcriptase enzyme to synthesize viral DNA. Once incorporated into the growing DNA chain, dexelvucitabine acts as a chain terminator, preventing further elongation of the viral DNA. This inhibition of viral DNA synthesis ultimately reduces the viral load in patients.

	==Clinical Trials ~~and Development~~==		==Development and Clinical Trials==
	~~Early~~ clinical trials ~~of dexelvucitabine~~ showed promise in reducing viral load in ~~individuals~~ with HIV~~/AIDS~~. However, ~~subsequent studies raised~~ concerns about ~~the drug's safety profile, particularly regarding its~~ potential ~~to cause mitochondrial~~ toxicity and ~~lactic acidosis, conditions that can be life-threatening. These safety concerns, coupled with the emergence of more effective and safer antiretroviral drugs~~, led to the discontinuation of ~~dexelvucitabine's~~ development.		Dexelvucitabine was developed in the early 2000s and underwent several phases of clinical trials. Initial studies showed promise in reducing viral load in patients with HIV. However, further trials revealed concerns about potential [[toxicity]] and adverse effects, which led to the discontinuation of its development.

	==~~Comparison with Other Antiretroviral Drugs~~==		==Adverse Effects==
	~~While~~ dexelvucitabine was ~~part of a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs)~~, ~~which are a cornerstone of modern~~ [[~~Antiretroviral Therapy\|antiretroviral therapy~~]] ~~(ART)~~, ~~it did not offer significant advantages over other drugs in the same class. Drugs such as~~ [[~~Lamivudine~~]] and [[~~Tenofovir~~]] ~~have better safety profiles and have been more extensively studied, making them preferred options in ART regimens~~.		During clinical trials, dexelvucitabine was associated with several adverse effects, including [[lactic acidosis]], [[hepatomegaly]], and [[steatosis]]. These side effects were significant enough to halt further development of the drug.

	==~~Conclusion~~==		==Chemical Properties==
	~~Although dexelvucitabine represented~~ a ~~novel approach~~ to ~~HIV/AIDS treatment during~~ its ~~development phase~~, its ~~potential risks outweighed the benefits~~. ~~The discontinuation of its development underscores the importance of safety and efficacy in the approval process for new medications. The focus in~~ HIV/AIDS ~~treatment remains on optimizing existing therapies and developing new drugs that offer improved outcomes with minimal side effects.~~		Dexelvucitabine is a synthetic analog of cytosine, with modifications that allow it to act as a reverse transcriptase inhibitor. Its chemical structure is designed to enhance its ability to be incorporated into viral DNA, while also aiming to reduce its degradation by cellular enzymes.

			==Related pages==
			* [[HIV/AIDS]]
			* [[Nucleoside reverse transcriptase inhibitor]]
			* [[Antiretroviral drug]]

	~~[[Category:HIV/AIDS]]~~
	[[Category:Antiretroviral drugs]]		[[Category:Antiretroviral drugs]]
	[[Category:~~Abandoned drugs~~]]		[[Category:Nucleoside analog reverse transcriptase inhibitors]]

	~~{{Medicine-stub}}~~

Prab: CSV import

2024-03-22T04:40:10Z

CSV import

New page

'''Dexelvucitabine''' is a nucleoside analogue antiretroviral medication that was under investigation for the treatment of [[HIV/AIDS]]. It is a synthetic analogue of deoxycytidine, designed to interfere with the life cycle of the [[HIV]] virus, thereby reducing the viral load in infected individuals. Despite initial research, development of dexelvucitabine was halted due to concerns over its safety profile and efficacy in comparison to other available treatments.

==Mechanism of Action==
Dexelvucitabine exerts its antiviral effects by acting as a competitive inhibitor of [[HIV reverse transcriptase]], an enzyme critical for the viral replication process. By incorporating itself into the viral DNA, dexelvucitabine causes chain termination. This prevents the completion of the DNA synthesis necessary for the replication of the HIV virus, leading to a decrease in viral load in the patient.

==Clinical Trials and Development==
Early clinical trials of dexelvucitabine showed promise in reducing viral load in individuals with HIV/AIDS. However, subsequent studies raised concerns about the drug's safety profile, particularly regarding its potential to cause mitochondrial toxicity and lactic acidosis, conditions that can be life-threatening. These safety concerns, coupled with the emergence of more effective and safer antiretroviral drugs, led to the discontinuation of dexelvucitabine's development.

==Comparison with Other Antiretroviral Drugs==
While dexelvucitabine was part of a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs), which are a cornerstone of modern [[Antiretroviral Therapy|antiretroviral therapy]] (ART), it did not offer significant advantages over other drugs in the same class. Drugs such as [[Lamivudine]] and [[Tenofovir]] have better safety profiles and have been more extensively studied, making them preferred options in ART regimens.

==Conclusion==
Although dexelvucitabine represented a novel approach to HIV/AIDS treatment during its development phase, its potential risks outweighed the benefits. The discontinuation of its development underscores the importance of safety and efficacy in the approval process for new medications. The focus in HIV/AIDS treatment remains on optimizing existing therapies and developing new drugs that offer improved outcomes with minimal side effects.

[[Category:HIV/AIDS]]
[[Category:Antiretroviral drugs]]
[[Category:Abandoned drugs]]

{{Medicine-stub}}